Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988544 | 0.97 | OPRD1 (0.70) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL12564203 | 0.95 | OPRD1 (0.73) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL12564266 | 0.92 | OPRD1 (0.71) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL1987011 | 0.92 | OPRD1 (0.63) | OPRD1OPRM1MEN1KMT2ALMNA | |
| SCHEMBL1989257 | 0.90 | OPRD1 (0.73) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL12019437 | 0.89 | OPRD1 (0.56) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL12564378 | 0.89 | OPRD1 (0.63) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL12564407 | 0.89 | OPRD1 (0.62) | OPRD1OPRM1MEN1KMT2ALMNA | |
| SCHEMBL12019375 | 0.88 | OPRD1 (0.55) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL1987888 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609659-B2 | Substituted 3,8-diazabicyclo[3.2.1]octane compounds | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2013-12-17 | — | — | US | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2338889-A1 | Diazacyclic compounds having affinity for opioid receptors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338889-A1 | Diazacyclic compounds having affinity for opioid receptors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885MEN1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.